
A new study shows nesolicaftor reverses cigarette smoke- and TGF-β1-induced mucociliary dysfunction in COPD by restoring CFTR and BK channel function, increasing ciliary beat, and reducing mucus viscosity. It works via PCBP1-mediated mRNA stabilization—shared with ARBs like losartan and telmisartan—highlighting a potential therapeutic path for COPD treatment.
Like
Save
Share